查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球諾羅病毒診斷市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按產品、按技術、按等級、按應用、按最終用戶、按地區
市場調查報告書
商品編碼
1394141

全球諾羅病毒診斷市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按產品、按技術、按等級、按應用、按最終用戶、按地區

Norovirus Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 245 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球諾羅病毒診斷市場規模預計在 2024 年至 2031 年間將以 8.7% 的複合年增長率 (CAGR) 快速增長，到 2031 年達到 1.3 億美元。 2024年市場規模為7,000萬美元，反映出當前的上升趨勢。

這一顯著增長的主要驅動力之一是諾羅病毒疾病發病率的上升。 該領域的主要參與者和製造商正在採用先進的技術來對抗這種高度傳染性的胃腸道病毒。 因此，醫療設備製造商正在增加研發 (R&D) 投資，以開發更靈敏、更有效率的先進診斷工具。 此類技術創新努力預計將在不久的將來刺激諾羅病毒診斷市場的擴張。

診斷實驗室的激增也促進了市場成長，這對製造商的銷售和利潤產生了積極影響。 隨著此類診斷實驗室的不斷出現，諾羅病毒診斷市場可能會大大受益。

然而，儘管成長前景廣闊，但也存在影響諾羅病毒診斷市場的某些障礙。 低收入國家諾羅病毒感染流行以及對諾羅病毒感染前症狀缺乏認識等因素阻礙了市場擴張。

諾羅病毒的診斷不足是影響患者健康的另一個問題，由於與該疾病相關的恥辱或對其症狀缺乏了解，個人可能不會尋求醫療救助。 諾羅病毒感染的症狀，如痙攣、噁心、嘔吐、腹瀉和低燒，容易與其他疾病混淆，導致誤診和忽視。 應對這些挑戰需要努力提高公眾意識並教育公眾有關諾羅病毒及其診斷方法的知識。

由於諾羅病毒感染率較高，美國在諾羅病毒診斷市場中佔有很大份額。 領先公司的存在和不斷增加的研發投資正在促進該市場的成長。 此外，旨在加強醫療保健系統和監管能力的政府措施預計將進一步推動市場擴張。

本報告調查了全球諾羅病毒診斷市場，並概述了市場概況、按產品、最終用戶、地區劃分的趨勢以及進入市場的公司的競爭趨勢。

目錄

第 1 章執行摘要

第二章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第 3 章2018-2031 年全球諾羅病毒診斷市場前景

  • 2018-2031 年全球諾羅病毒診斷市場前景（按產品和價值劃分）（百萬美元）
  • 全球諾羅病毒診斷市場展望，按最終用戶劃分，價值（百萬美元），2018-2031 年
  • 2018-2031 年全球諾羅病毒診斷市場前景（按地區、價值（百萬美元））

第 4 章北美諾羅病毒診斷市場前景，2018-2031

第 5 章歐洲諾羅病毒診斷市場前景，2018-2031

第 6 章亞太地區諾羅病毒診斷市場展望，2018-2031 年

第 7 章拉丁美洲諾羅病毒診斷市場展望，2018-2031 年

第 8 章中東與非洲諾羅病毒診斷市場前景，2018-2031

第九章競爭態勢

  • 製造商和最終用戶的熱圖
  • 2023 年公司市佔率分析
  • 競爭力儀表板
  • 公司簡介
    • Abbott Laboratories
    • R-Biopharm AG
    • ELITechGroup AG
    • Danaher Corporation (Cepheid)
    • Meridian Bioscience Inc.
    • Eiken Chemical Co.
    • Altona Diagnostics GmbH
    • Elisabeth Pharmacon, Spol. S Ro
    • CerTest Biotec S.L
    • Altona Diagnostics GmbH

第 10 章附錄

簡介目錄

The global Norovirus Diagnostics Market is set to witness substantial growth, with the market projected to surge at a Compound Annual Growth Rate (CAGR) of 8.7% between 2024 and 2031, reaching an estimated valuation of US$ 130.0 Mn by the end of the forecast period. In 2024, the market stood at a value of US$ 70 Mn, reflecting its current upward trajectory.

Rising Incidence of Norovirus Disease

One of the key driving factors behind this remarkable growth is the escalating incidence of norovirus disease. Leading participants and manufacturers in the field are adopting sophisticated techniques to combat this highly contagious stomach and intestinal virus. As a result, medical device companies have increased their Research and Development (R&D) investments to develop advanced diagnostic tools that are more sensitive and efficient. This commitment to innovation is expected to fuel the expansion of the Norovirus Diagnostics Market in the near future.

The proliferation of diagnostics laboratories is also contributing to the market's growth, bringing about favorable effects on sales and revenue for manufacturers. As these diagnostics labs continue to emerge, the market for norovirus diagnostics is set to benefit significantly.

Lack of Awareness about Norovirus

However, despite the promising growth prospects, there are certain impediments affecting the Norovirus Diagnostics Market. Factors such as the prevalence of norovirus infection in low-income nations and the lack of awareness about the symptoms preceding norovirus infection have hindered the market's expansion.

The underdiagnosis of norovirus is another issue impacting patient health, as individuals may not seek medical attention due to the stigma associated with the disease or a lack of understanding about its symptoms. The symptoms of norovirus infection, including cramps, nausea, vomiting, diarrhea, and low-grade fever, can be easily confused with other illnesses, leading to misdiagnosis or neglect. To address these challenges, efforts are needed to raise awareness and educate the public about norovirus and its diagnostic options.

Booming U.S. Market

The United States holds a significant share of the Norovirus Diagnostics Market due to the high prevalence of norovirus infections in the country. The presence of major companies and increased R&D investments have contributed to the growth of this market. Additionally, government initiatives aimed at strengthening healthcare systems and regulatory capacities are expected to further propel market expansion.

Lucrative Prospects in Germany's Medical Wellness Market

In Germany, the medical wellness market is thriving, primarily driven by the country's strong emphasis on fitness and well-being. Major players in the industry are collaborating to develop new products, enhancing the market's growth potential.

China Emerges as a Prominent Market for Medical Wellness

China is becoming a prominent market for medical wellness, with manufacturers focusing on expanding their global presence, expertise, and technological capabilities. This strategic approach is making norovirus diagnostics products more widely accessible in the Chinese market.

Competitive Landscape Analysis

The introduction and approval of innovative products are central elements of these manufacturers' strategies to enhance their market presence.

Key Companies Profiled:

  • Abbott
  • R-Biopharm AG
  • ELITechGroup AG
  • Danaher Corporation (Cepheid)
  • Meridian Bioscience Inc.
  • Eiken Chemical Co.
  • Altona Diagnostics GmbH
  • CerTest Biotec S.L
  • Elisabeth Pharmacon, Spol. S Ro
  • Qiagen
  • Altona Diagnostics GmbH
  • Eiken Chemical Co

With the global norovirus diagnostic market on a steady growth trajectory, these developments and trends highlight the promising future of diagnostics for norovirus infection, offering hope for more accurate and timely detection and treatment.

Key Segments Covered in Norovirus Diagnostics Industry Research

By Product

  • Rapid Test Kits
  • PCR Kits
  • ELISA based kits

By End-User

  • Hospitals
  • Diagnostics Labs
  • Clinics

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Norovirus Diagnostics Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 3.1. Global Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Rapid Test Kits
      • 3.1.1.2. PCR Kits
      • 3.1.1.3. ELISA based kits
  • 3.2. Global Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospitals
      • 3.2.1.2. Diagnostics Labs
      • 3.2.1.3. Clinics
  • 3.3. Global Norovirus Diagnostics Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 4.1. North America Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Rapid Test Kits
      • 4.1.1.2. PCR Kits
      • 4.1.1.3. ELISA based kits
  • 4.2. North America Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospitals
      • 4.2.1.2. Diagnostics Labs
      • 4.2.1.3. Clinics
    • 4.2.2. BPS Analysis/Market Attractiveness Analysis
  • 4.3. North America Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 4.3.1.2. U.S. Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.3.1.3. Canada Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 4.3.1.4. Canada Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 5.1. Europe Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Rapid Test Kits
      • 5.1.1.2. PCR Kits
      • 5.1.1.3. ELISA based kits
  • 5.2. Europe Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospitals
      • 5.2.1.2. Diagnostics Labs
      • 5.2.1.3. Clinics
    • 5.2.2. BPS Analysis/Market Attractiveness Analysis
  • 5.3. Europe Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.2. Germany Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.3. U.K. Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.4. U.K. Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.5. France Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.6. France Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.7. Italy Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.8. Italy Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.9. Turkey Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.10. Turkey Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.11. Russia Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.12. Russia Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Rapid Test Kits
      • 6.1.1.2. PCR Kits
      • 6.1.1.3. ELISA based kits
  • 6.2. Asia Pacific Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospitals
      • 6.2.1.2. Diagnostics Labs
      • 6.2.1.3. Clinics
    • 6.2.2. Others BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.2. China Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.3. Japan Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.4. Japan Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.5. South Korea Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.6. South Korea Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.7. India Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.8. India Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 7.1. Latin America Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Rapid Test Kits
      • 7.1.1.2. PCR Kits
      • 7.1.1.3. ELISA based kits
  • 7.2. Latin America Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
      • 7.2.1.1. Hospitals
      • 7.2.1.2. Diagnostics Labs
      • 7.2.1.3. Clinics
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.3.1.2. Brazil Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.3. Mexico Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.3.1.4. Mexico Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.5. Argentina Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.3.1.6. Argentina Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Norovirus Diagnostics Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Norovirus Diagnostics Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Rapid Test Kits
      • 8.1.1.2. PCR Kits
      • 8.1.1.3. ELISA based kits
  • 8.2. Middle East & Africa Norovirus Diagnostics Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospitals
      • 8.2.1.2. Diagnostics Labs
      • 8.2.1.3. Clinics
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Norovirus Diagnostics Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.2. GCC Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.3. South Africa Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.4. South Africa Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.5. Egypt Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.6. Egypt Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.7. Nigeria Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.8. Nigeria Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Norovirus Diagnostics Market by Product, Value (US$ Mn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Norovirus Diagnostics Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Manufacturer vs by End User Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Abbott Laboratories
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. R-Biopharm AG
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. ELITechGroup AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Danaher Corporation (Cepheid)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Meridian Bioscience Inc.
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Eiken Chemical Co.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Altona Diagnostics GmbH
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Elisabeth Pharmacon, Spol. S Ro
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. CerTest Biotec S.L
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Altona Diagnostics GmbH
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations